Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 18, 2007 Brian Lawler	MGI's Quiet Gains The specialty pharma notches a healthy third-quarter and should keep performing well into the future. Investors, take note.
The Motley Fool September 3, 2004 Charly Travers	MGI Pharma's Shopping Spree The company is filling out its drug pipeline with acquisitions.
The Motley Fool July 24, 2007 Brian Lawler	MGI Flies Shares of MGI Pharma rise after positive second-quarter results and a bright outlook for the coming months.
The Motley Fool December 11, 2007 Brian Lawler	The MGI Deal Makes Sense MGI Pharma announces it is being acquired by Japanese pharma giant Eisai for $3.9 billion.
The Motley Fool November 30, 2007 Brian Lawler	MGI's Turn for "Strategic Alternatives" MGI Pharma is the latest in a growing list of drugmakers looking for someone to acquire them. The company may be a relatively more attractive takeover target than other drugmakers, because it's two lead drugs are unpartnered in the U.S.
The Motley Fool May 26, 2011 Brian Orelli	Congress Sets Bad Precedent With AVANIR What happened to free markets?
The Motley Fool June 11, 2007 Brian Lawler	Johnson & Johnson's Pretty Pipeline While there are concerns about other parts of Johnson & Johnson (for example, its medical device segment), its pharmaceutical division has a robust pipeline of compounds in development that should pay off in the long haul.
The Motley Fool December 4, 2007 Brian Lawler	Another Drug Deal Goes Down Canadian specialty pharma Axcan Pharma became the latest drugmaker to be acquired by a private equity group -- for $1.3 billion in cash.
BusinessWeek August 9, 2004 Gene G. Marcial	MGI Pharma Has Just What Patients Need Its first major drug, an injection to prevent chemotherapy-induced nausea and vomiting, is on fire in a $1.5 billion market. And turning MGI into a moneymaker.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
The Motley Fool October 16, 2006 Brian Lawler	MGI Drug Approval Falters The FDA gives the thumbs-down to Saforis. However, investors should take notice of this well-run pharmaceutical.
InternetNews July 27, 2010	Oracle Debuts Drug-Tracking App for Big Pharma With its new Pedigree and Serialization Manager, Oracle is pitching an application to pharmaceutical companies that will enable them to track the movement of drugs across the supply chain.
Chemistry World November 18, 2010 Ned Stafford	New drug pricing rules in Germany The law was approved on 11 November and will take effect from 1 January as part of an effort to rein in exploding costs for Germany's massive public health insurance system.
The Motley Fool September 9, 2004 Charly Travers	The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated.
The Motley Fool December 21, 2010 Brian Orelli	4 Drugmakers, 5 Deals, Christmas Is Here It looks like there were a lot of people in the business development offices at pharmaceutical companies looking to get their work done before taking off for the holidays. Check out all the deals that were announced yesterday.
The Motley Fool October 18, 2010 Brian Orelli	Pfizer Flexes Its Generic Muscles The pharma giant moves farther into generic drugs.
The Motley Fool April 6, 2011 Brian Orelli	Merck Inspired to Eye Growth A bolt-on acquisition of eye-care specialist Inspire.
The Motley Fool January 31, 2011 Brian Orelli	Pharma Goes Back to School But will it produce more drugs? The pharmaceutical industry is headed back to school, with a number of large drugmakers announcing partnerships with universities.
Pharmaceutical Executive September 1, 2006 Patrick Clinton	From the Editor: Undecided People are buying drugs, because companies are selling drugs. Interfere with the selling process, and people won't buy as many drugs.
The Motley Fool April 5, 2011 Frank Vinluan	Tranzyme Pharma's Public Offering Raises $48M, but IPO Has Little Bounce Tranzyme Pharma likely had hopes for an opening bounce on the day the drug development company went public, but that ball fell flat.
The Motley Fool June 2, 2009 Brian Orelli	ASCO's Big Winner Despite the massive changes in value that some small-cap biotech companies have seen before and during this year's American Society of Clinical Oncology annual meeting, the big winner from the confab is actually large pharmaceutical companies.
The Motley Fool January 28, 2010 Brian Orelli	How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward.
The Motley Fool December 31, 2010 Brian Orelli	How the Other Half of Pharma Lives A dive into spec pharma.
Chemistry World March 27, 2013 Eugene Gerden	Russian investment vehicle sets sights on innovative drugs Russian state-owned nanotechnology giant Rusnano is hoping to break into the pharmaceutical sector with sizeable investments in firms seeking to produce innovative drugs.
Chemistry World September 11, 2014 Emma Stoye	Pharma sales 'will reach $1 trillion' in 2014 Global sales in the pharmaceutical industry are set to go over the $1 trillion mark this year, according to a report by Thomson Reuters.
BusinessWeek March 12, 2007 Gene G. Marcial	SuperGen Is Looking Healthier Biotechs are gaining traction this year as fund managers discover many with viable products that are still underpriced.
The Motley Fool December 28, 2004 Charly Travers	It's All in the Delivery If too much risk makes you queasy, these drug companies are for you. SkyePharma... DepoMed...
BusinessWeek November 29, 2004 Catherine Arnst	Big Pharma's Blinders Hugely profitable thanks to a few blockbusters, Big Pharma is far too focused on looking for the next best-seller, causing companies to pass up opportunities to deliver important breakthroughs.
The Motley Fool December 29, 2006 Brian Lawler	No Pain for Alexza December's been good to lots of pharmas, but Alexza in particular has something to thank Santa for. Investors should pay close attention when Alexza issues its AZ-001 trial results next year.
Pharmaceutical Executive December 1, 2008 Patrick Clinton	Reason to Believe Here are a few things to be optimistic about in the pharmaceutical industry.
The Motley Fool October 23, 2006 Brian Lawler	No Slowing Novartis The Swiss pharmaceutical company shows strength in nearly all its divisions. Novartis looks like a good investment for risk-adverse investors searching for a large-cap pharma stock.
Information Today October 2000	Dialog One Releases New Pharmaceutical Module With Dialog One Pharmaceutical, users can discover what new drugs their competitors have in development, follow regulatory information for pharmaceuticals and medical devices, and uncover lucrative drug licensing opportunities worldwide...
Pharmaceutical Executive October 1, 2008 Patrick Clinton	Future Shock A vision of pharma's next business model is starting to emerge. But how do we get from here to there?
Pharmaceutical Executive June 1, 2006 Philip A. George	Alternative Media: Online Med Sites Gain Patient Trust Pharma could benefit from a little less TV.
The Motley Fool January 31, 2007 Brian Lawler	FDA Says Hurray for More Drug Safety The FDA outlines its proposal to increase drug safety. Whatever the FDA does, pharmaceutical investors should hope that its renewed interest in drug safety doesn't make the already lengthy process of bringing drugs to market any longer.
The Motley Fool December 6, 2004 Brian Gorman	Pill-Popping Nation Americans are using more prescription drugs. Unfortunately for big pharma investors, pharmaceutical companies' benefits from these trends are tempered by other factors.
The Motley Fool August 27, 2009 Brian Orelli	The List You Have to Be On Good for you if your company's products made the cut in China. This sounds like a growth opportunity for American Oriental Bioengineering and anyone else who can get a place on the list.
The Motley Fool December 12, 2007 Brian Lawler	Patent Bill Is No Panacea A new bill that was meant to strengthen the patent and other intellectual-property rights of drugmakers doesn't do enough to encourage pharma innovation.
The Motley Fool March 6, 2009 Brian Orelli	For Drug Companies, R&D Is Spelled C-R-O It seems likely that more and more pharma companies will try to get more bang for their bucks by spending them on research and development done outside the company, outsourcing it to clinical research organizations.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
CRM February 2, 2003 David Myron	Vertical Focus: Pharmaceuticals Pharmaceutical companies are prolonging the good health of their customers -- and the CRM industry. Largely influenced by retiring Baby Boomers, lack of FDA-approved drugs in the pipeline, and direct selling campaigns, the industry is becoming more customer-focused.
Pharmaceutical Executive October 1, 2005 Philip A. George	Backpage: Under Surveillance Doctors and consumers don't doubt that pharma benefits society. But in the eyes of the public, industry efforts to monitor postmarket safety come up short.
The Motley Fool July 20, 2006 Stephen D. Simpson	Wyeth Wins Again Another respectable quarter and a decent pipeline make this pharmaceutical stock worth watching.
The Motley Fool April 24, 2006 Stephen D. Simpson	Novartis: A Good Story Repeated Whether sales were a little light or not, this is still a high-quality pharmaceutical company. The company not only has a good pipeline, but the valuation is still attractive without needing to make particularly aggressive assumptions.
Chemistry World November 2010	Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream?
The Motley Fool September 12, 2005 M.D. Mitchell	Big Problems for Big Pharma Creating new drugs is never easy, but the companies that excel in three key areas are the ones for investors to watch.
The Motley Fool January 25, 2007 Brian Lawler	Johnson & Johnson's Earnings Glee Johnson & Johnson keeps growing, even if the pharmaceutical segment is a bit sluggish. Investors, take note.
The Motley Fool December 21, 2004 Charly Travers	Invest With Fewer Side Effects Averse to risk? Check out these nontraditional drug companies: Biogen Idec... Elan... Salix Pharmaceuticals... Atrix Laboratories... etc.
The Motley Fool December 20, 2007 Brian Orelli	2007: The Year Pharma Fell in Love With Biologics The reason for pharma's newfound infatuation for biotech is quite clear. Many pharmaceutical companies are facing a patent cliff in the coming years, and they need to replace their blockbusters with something.
BusinessWeek October 18, 2004 Catherine Arnst	The Waning of the Blockbuster Drug What's promising now are drugs that target niche diseases. That means painful restructuring ahead for Big Pharma